Dual Immune Checkpoint Blockade for Advanced Hepatocellular Carcinoma

1. Adding anti-CTLA4 antibody to PD1 blockade improves treatment response of advanced HCC
2. Nivolumab + ipilimumab has been approved for patients after sorafenib treatment failure in USA
3. Management of adverse events is crucial for using dual CTLA4 and PD1 blockade
4. Whether dual CTLA4 and PD1 blockade can be used as first-line therapy for advanced HCC remained to be explored